{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.","groups":[{"description":"Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT + Cisplatin"},{"description":"Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Cisplatin + Vandetanib"}],"reportingStatus":"POSTED","timeFrame":"From randomization to date of failure (local, regional, or distant progression, or death) or last follow-up. Analysis occurs after 78 failures have been reported.","title":"Disease-free Survival","type":"PRIMARY"}